FDA’s Center for Veterinary Medicine approved Elanco US Inc.’s NADA for ELURA™ on Oct. 16th, 2020. Elura™ is an oral solution of capromorelin developed for the management of weight loss in cats with chronic kidney disease (CKD). This is the first drug specifically approved for weight gain and appetite stimulation in cats diagnosed with CKD and KFI was pleased to conduct the fed/fasted PK study in support of Elanco US Inc.’s new drug approval.
